One of the most respected and influential groups in the continuing breast-cancer screening debate said on Tuesday that women should begin mammograms later and have them less frequently than it had long advocated.
The American Cancer Society,
which has for years taken the most aggressive approach to screening,
issued new guidelines on Tuesday, recommending that women with an
average risk of breast cancer
start having mammograms at 45 and continue once a year until 54, then
every other year for as long as they are healthy and expected to live
another 10 years.
The
organization also said it no longer recommended clinical breast exams,
in which doctors or nurses feel for lumps, for women of any age who have
had no symptoms of abnormality in the breasts.
Previously, the society recommended mammograms and clinical breast exams every year, starting at 40.
The
changes reflect increasing evidence that mammography is imperfect, that
it is less useful in younger women, and that it has serious drawbacks,
like false-positive results that lead to additional testing, including
biopsies.
But
the organization’s shift seems unlikely to settle the issue. Some other
influential groups recommend earlier and more frequent screening than
the cancer society now does, and some recommend less, leaving women and
their doctors to sort through the conflicting messages and to figure out
what makes the most sense for their circumstances.
In fact, although the new guidelines may seem to differ markedly from the old ones, the American Cancer Society
carefully tempered its language to leave plenty of room for women’s
preferences. Though it no longer recommends mammograms for women ages 40
to 44, it said those women should still “have the opportunity” to have
the test if they choose to, and that women 55 and older should be able
to keep having mammograms once a year.
This year, 231,840 new cases of invasive breast cancer and 40,290 deaths are expected in the United States.
The new guidelines were published on Tuesday in the Journal of the American Medical Association, along with an editorial and an article on the benefits and risks of screening, which provided evidence for the guidelines. A separate article and editorial on the subject were also published in another journal, JAMA Oncology.
The
guidelines apply only to women at average risk for breast cancer —
those with no personal history of the disease or known risk factors
based on genetic mutations, family history or other medical problems.
The
changed policy resulted from an exhaustive review of research data,
which the cancer society conducts regularly to update its screening
guidelines, said Dr. Richard C. Wender, the organization’s chief cancer
control officer. The last review was in 2003, and this one took about
two years.
Dr. Wender said he hoped the new guidelines would end some of the debate
and confusion about mammography. But some doubted that the guidelines
would bring clarity.
“I
think it has the potential to create a lot of confusion amongst women
and primary care providers,” said Dr. Therese B. Bevers, the medical
director of the Cancer Prevention Center at the University of Texas M.
D. Anderson Cancer Center in Houston.
Dr.
Nancy L. Keating, a professor of health care policy and medicine at
Harvard and a co-author of the JAMA editorial about the guidelines, said
she thought the new advice had been thoughtfully developed and was
headed in the right direction. Dr. Keating, who practices at Brigham and
Women’s Hospital in Boston, said doctors and patients had clung to the
practice of early and yearly mammograms out of fear that they would
otherwise miss detecting a cancer.
The National Comprehensive Cancer Network, an alliance of prominent cancer centers, recommends mammograms every year starting at age 40. The American College of Obstetricians and Gynecologists
recommends them every year or two from ages 40 to 49, and every year
after that. It also recommends yearly clinical breast exams starting at
age 19.
The
obstetricians’ group said it was convening a conference in January,
with the participation of the American Cancer Society, the comprehensive
cancer network and other organizations, to try to develop a consistent
set of guidelines.
Among those invited are the United States Preventive Services Task Force,
which recommends less testing: mammograms every other year for women
ages 50 to 74. In 2009, it advised against routine mammograms for women
ages 40 to 49, a decision that ignited a firestorm of protests from
doctors, patients and advocacy groups.
The
task force, an independent panel of experts appointed by the Department
of Health and Human Services, softened its approach in draft guidelines
that were posted on its website in April and have yet to be finalized.
Instead of advising against routine screening for women in their 40s,
the group now says, “The decision to start screening mammography in
women before age 50 years should be an individual one.”
But
the task force gave the evidence for screening women under 50 a rating
of “C,” reflecting its belief that the benefit is small. Services with a
C rating do not have to be covered by the Affordable Care Act,
according to the Department of Health and Human Services — a serious
worry for advocates.
In response to the new cancer society guidelines, the task force issued a
statement saying it would “examine the evidence” the cancer society had
developed and reviewed before finalizing its recommendations. The
statement also noted that the task force recognized “that there are
health benefits to beginning mammography screening for women in their
40s.”
In
making recommendations about screening, experts try to balance the
benefits of a test against its potential harms for women in various age
groups. A general explanation of the reasoning behind the new guidelines
is that breast cancer is not common enough in women under 45 to make
mammograms worthwhile for that age group, but that the risk of the
disease increases enough to justify screening once a year after that.
Specifically, the risk of developing breast cancer during the next five
years is 0.6 percent in women ages 40 to 44; 0.9 percent from 45 to 49;
and 1.1 percent from 50 to 54.
The risk keeps increasing slowly with age, but by 55, when most women have passed through menopause,
tumors are less likely to be fast-growing or aggressive, and breast
tissue changes in ways that make mammograms easier to read — so
screening every other year is considered enough.
As
for the decision to stop recommending clinical breast exams, the
society said that there was no evidence that the exams save lives, but
that there was evidence that they could cause false positives — meaning
they could mistakenly suggest problems where none existed and lead to
more tests. The exams can take five or six minutes that could be put to
better use during office visits, said Dr. Kevin C. Oeffinger, the
chairman of the cancer-society subgroup that developed the guidelines
and director of cancer survivorship at Memorial Sloan Kettering Cancer
Center in New York.
According
to the evidence review accompanying the guidelines, the benefit of
regular mammography is that it can reduce the risk of dying from breast
cancer by about 20 percent. Because breast cancer is less common in
younger women, their baseline risk of dying is lower, and screening them
saves fewer lives.
While
younger women have less to gain from mammograms, the cancer society
found, they incur all the potential harms. One harm is false positives,
which can lead to more tests, including biopsies. A 2011 study cited in
the article explaining the new guidelines found that 61 percent of women
who had yearly mammograms starting at age 40 had at least one false
positive by the time they were 50. Being tested every other year instead
of every year can cut the false positive rate significantly, the JAMA
Oncology article explaining the guidelines said, to about 42 percent
from 61 percent.
Some
women consider false positives a small price to pay for the chance of
identifying a cancer early. Others find being called back for more tests
too nerve-racking.
Another
potential risk of mammography is overdiagnosis, meaning that some of
the tiny cancers it finds might never progress or threaten the patient’s
life. But because there is now no way to be sure which will turn
dangerous, they are treated anyway.
There
are no widely accepted figures on how often overdiagnosis occurs.
Researchers think that it is mostly likely in women found to have ductal
carcinoma in situ, or D.C.I.S., tiny growths in the milk ducts that may
or may not evolve into invasive cancer. About 60,000 cases of D.C.I.S.
are diagnosed in the United States each year.
“We
would all love to avoid diagnosing and treating a breast cancer that
doesn’t need treatment,” Dr. Oeffinger said. “But we don’t have the
tools.”
But,
he added: “This area is rapidly changing. In five to seven years, we’ll
have more knowledge in this area that will let us be more personalized
in our approach.”
Dr.
Keating said, “Radiologists are working hard to find new and better
screening tests, which we desperately need, but I think it will take
time.”
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου